What are the appropriate follow‑up investigations and possible causes for a neutrophil count of 1.43 × 10⁹/L with hypogranular neutrophils?

Neutrophil Count of 1.43 × 10⁹/L with Hypogranular Neutrophils: Evaluation and Differential Diagnosis

A neutrophil count of 1.43 × 10⁹/L with hypogranular neutrophils should prompt immediate evaluation for myelodysplastic syndrome (MDS), as hypogranulation is a characteristic dysplastic feature present in 65-84% of MDS cases and represents a key diagnostic finding. 1

Immediate Follow-Up Investigations

Essential First-Line Testing

Bone marrow evaluation is mandatory and should include:

• Bone marrow aspiration with iron stain
• Bone marrow biopsy
• Conventional karyotype/cytogenetic analysis 2, 3

This triad is essential because MDS diagnosis requires assessment of dysplasia across lineages, blast percentage, and cytogenetic abnormalities—all of which determine prognosis and treatment strategy.

Critical Peripheral Blood Work

• Complete blood count with differential and reticulocyte count
• Peripheral blood smear examination to quantify:
  • Percentage of hypogranular/agranular neutrophils
  • Pelgeroid nuclear abnormalities (pseudo-Pelger-Huët cells)
  • Dysplasia in other lineages 2, 3

Important caveat: Hypogranulation combined with pelgeroid changes detects peripheral blood dysplasia in 92% of MDS cases 1. When both features are present, MDS becomes highly likely.

Automated Hematology Parameters

Modern analyzers provide quantitative dysplasia markers:

• NEUT-X/NEUT-GI values (reflecting cytoplasmic granularity)
• NEUT-Y values (reflecting nucleic acid/protein content)

Values of NEUT-X <1,315 and NEUT-Y <400 simultaneously are highly specific for MDS 4. This provides objective quantification beyond subjective microscopy.

Additional Laboratory Studies

• Serum erythropoietin (EPO) level - critical for treatment decisions if MDS confirmed 3
• Vitamin B12, folate levels - rule out nutritional causes 3
• Autoimmune workup if clinically indicated
• Medication review - drug-induced neutropenia accounts for 5.9% of cases 5

Differential Diagnosis Framework

Primary Concern: Myelodysplastic Syndrome

Your neutrophil count of 1.43 × 10⁹/L meets WHO 2016 MDS criteria for neutropenia (defined as <1.8 × 10⁹/L) 2. Combined with hypogranulation, this raises significant concern for MDS.

MDS classification depends on:

• Number of dysplastic lineages (1,2, or 3)
• Blast percentage in marrow and blood
• Presence of ring sideroblasts
• Cytogenetic abnormalities 2

Prognostic scoring uses the IPSS-R system, which incorporates:

• Cytogenetic risk category
• Bone marrow blast percentage
• Hemoglobin level
• Platelet count
• Absolute neutrophil count (your value of 1.43 scores 0 points, as it's >0.8 × 10⁹/L) 2

Alternative Etiologies to Exclude

Benign ethnic neutropenia (Duffy null phenotype):

• Most common cause of isolated neutropenia in referred patients (29.4%) 5
• Exclusively in individuals of African heritage
• Median ANC typically 1.42 × 10⁹/L (remarkably similar to your value) 5
• Key distinguishing feature: No hypogranulation or dysplastic changes
• No history of recurrent infections
• Testing: Duffy antigen phenotyping should be first-line in appropriate ethnic backgrounds 5

Autoimmune neutropenia:

• Accounts for 20.6% of isolated neutropenia cases 5
• May have associated autoimmune conditions
• Typically lacks dysplastic morphology

Drug-induced neutropenia:

• Represents 5.9% of cases 5
• Temporal relationship with medication exposure
• Usually resolves with drug discontinuation

Infection-related:

• Viral infections can cause transient neutropenia
• Typically self-limited without dysplastic features 6

Critical Clinical Context

Historical Neutrophil Trends

The timing and trajectory of neutrophil decline is crucial 6:

• Acute drop suggests infection or drug reaction
• Chronic stable neutropenia favors benign ethnic variant
• Progressive decline with emerging dysplasia suggests MDS

Infection History

• Absence of recurrent infections argues against severe congenital neutropenia and supports benign causes 5
• Presence of severe infections with neutropenia may require aggressive management, though not directly related to dysplasia etiology 7

Age and Demographics

MDS typically affects older adults, with median survival and AML progression risk stratified by IPSS-R score 2. Younger patients with isolated neutropenia and African heritage should be evaluated for Duffy null phenotype first 5.

Common Pitfalls to Avoid

1. Do not dismiss hypogranulation as artifact: Quantitative assessment using granulation scores or automated parameters (NEUT-X/NEUT-Y) provides objective confirmation 1, 4

2. Do not assume all dysplastic cells are clonal: Only 6-43% of hypogranulated neutrophils may carry chromosomal abnormalities in some MDS cases 8. Cytogenetic analysis of marrow is essential.

3. Do not delay bone marrow biopsy: Peripheral blood findings alone cannot definitively diagnose or exclude MDS 2, 3

4. Do not overlook Duffy null testing in appropriate populations: This benign condition mimics pathologic neutropenia but requires no treatment 5

5. Do not forget to check EPO levels early: If MDS is confirmed, EPO levels guide first-line therapy selection (ESAs vs. luspatercept vs. imetelstat vs. lenalidomide depending on cytogenetics and RS status) 3

Risk Stratification if MDS Confirmed

Bone marrow failure (infection and hemorrhage) is the leading cause of death in MDS before AML transformation 2. Your neutrophil count places you at risk for infectious complications, making prompt diagnosis and risk stratification essential for determining whether you need:

• Observation only (very low/low risk)
• Disease-modifying therapy (intermediate/high/very high risk)
• Consideration for allogeneic transplantation (higher-risk disease)